☆ 4.6 Article

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

VIRUSES-BASEL (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Multidisciplinary

A Selective SARS-CoV-2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species

Cong Tang et al.

Summary: The emergence of SARS-CoV-2 prompted the development of vaccines and antivirals. However, direct-acting antiviral drugs are vulnerable to viral mutations. A host-directed antiviral called piperlongumine (PL) was found to induce reactive oxygen species in infected cells, showing robust antiviral activity. In a mouse model, intranasal administration of PL was superior in delaying disease progression and reducing lung inflammation. Importantly, PL was effective against several variants of concern, expanding the arsenal of tools against future outbreaks.

ACS CENTRAL SCIENCE (2023)

Add to Collection

Article Virology

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

David E. Martin et al.

Summary: This study suggests that treating symptomatic mild-to-moderate COVID-19 patients with probenecid can significantly decrease the time to viral clearance and result in a higher proportion of complete symptom resolution by day 10.

VIRUSES-BASEL (2023)

Add to Collection

Article Chemistry, Applied

One-Pot Synthesis of Molnupiravir from Cytidine

Tianwen Hu et al.

Summary: A one-pot process for preparing molnupiravir from cytidine was developed, which achieved high purity through selective protection of cytidine moieties and mild conditions to avoid degradation, and improved synthetic efficiency by combining deprotection and hydroxyamination into one step.

ORGANIC PROCESS RESEARCH & DEVELOPMENT (2022)

Add to Collection

Article Pharmacology & Pharmacy

Why 90 % of clinical drug development fails and how to improve it?

Duxin Sun et al.

Summary: Despite the implementation of many successful strategies, the majority of clinical drug development fails. This study suggests that current drug optimization strategies overlook tissue exposure/selectivity, leading to misleading drug candidate selection and impacting clinical efficacy/toxicity balance. The proposed structure-tissue exposure/selectivity-activity relationship (STAR) classification system aims to improve drug optimization and enhance the success rate of clinical drug development.

ACTA PHARMACEUTICA SINICA B (2022)

Add to Collection

Article Biochemical Research Methods

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry

Miao Xu et al.

Summary: In this study, a cell-based SARS-CoV-2 entry assay using viral pseudotyping was established and several active compounds inhibiting SARS-CoV-2 entry were identified. The assay demonstrated its utility in the discovery and development of entry inhibitors and the mechanistic study of anti-SARS-CoV-2 compounds.

SLAS DISCOVERY (2022)

Add to Collection

Review Virology

Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication

Ralph A. Tripp et al.

Summary: Viral replication and transmissibility are the main causes of endemic and pandemic disease threats. Broad-spectrum antiviral agents are needed. The most common respiratory viruses are coronaviruses, respiratory syncytial viruses, and influenza viruses. Probenecid has been shown to be safe and effective in limiting the replication of influenza A virus and SARS-CoV-2, as well as inhibiting RSV replication in vitro and in vivo.

VIRUSES-BASEL (2022)

Add to Collection

Article Virology

Biophysical Modeling of SARS-CoV-2 Assembly: Genome Condensation and Budding

Siyu Li et al.

Summary: The study reveals the self-assembly of SARS-CoV-2 virus structural proteins into infectious virus, with N protein interacting and condensing RNA for packaging and M protein's curvature being crucial for virus budding. Despite current focus on S protein and vaccine development, understanding details of viral life cycle and identifying alternative drug targets are essential due to mutations in the crucial protein.

VIRUSES-BASEL (2022)

Add to Collection

Article Chemistry, Medicinal

Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents

Joshua E. Hochuli et al.

Summary: This study investigates whether compounds that bind the human angiotensin-converting enzyme 2 (ACE2) protein can reduce SARS-CoV-2 replication without affecting ACE2's enzymatic function. Through screening and in silico techniques, 73 ACE2 binders were identified, and five of them were found to inhibit the viral life cycle in human cells. These compounds serve as valuable starting points for the development of acute treatments for COVID-19 and research into host-directed therapy.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Microbiology

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

Tianling Ou et al.

Summary: Chloroquine and hydroxychloroquine have been shown to inhibit viral infection by targeting different pathways through which the SARS-CoV-2 spike protein is activated. SARS-CoV-2 relies more on the TMPRSS2 pathway for entry, while the presence of a furin-cleavage site in its spike protein further complicates the treatment with hydroxychloroquine alone. Combining hydroxychloroquine with a TMPRSS2 inhibitor may provide a more effective strategy to block SARS-CoV-2 infection.

PLOS PATHOGENS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

Catherine Z. Chen et al.

Summary: Drug repurposing is a fast approach to identify therapeutics for emerging infectious diseases like COVID-19. A study identified and confirmed 319 compounds with anti-SARS-CoV-2 activities, including 230 compounds with previously unreported activities. Chlorprothixene, methotrimeprazine, and piperacetazine, three FDA-approved drugs, showed potent anti-SARS-CoV-2 activities, which were not previously reported.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo

Eun-Jung Song et al.

Summary: The study found that the serine protease inhibitor aprotinin has inhibitory effects on a wide range of influenza virus subtypes, including avian influenza viruses and oseltamivir-resistant influenza viruses, and significantly increased survival rate in mice infected with a lethal dose of influenza virus. This suggests that aprotinin could be considered for development as a therapeutic agent against influenza.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Pharmacology & Pharmacy

The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19

Elangovan Manivannan et al.

Summary: The rapid spread and high mortality rate of COVID-19 have posed a global public health challenge. Chloroquine and hydroxychloroquine were initially considered for the treatment of COVID-19, but their authorization was later revoked by FDA and WHO, emphasizing the need for evidence-based treatment protocols to address the pandemic.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase

Jianyuan Zhao et al.

Summary: Antiviral therapeutics are crucial in combating the COVID-19 pandemic, and a cell-based assay for SARS-CoV-2 RdRp has been developed to evaluate the efficacy of nucleotide analog inhibitors and their resistance to viral exoribonuclease-mediated proofreading. Molnupiravir and Remdesivir showed strong inhibition of SARS-CoV-2 RdRp, with Molnupiravir demonstrating the lowest EC50 value and Remdesivir having the highest resistance to exoribonuclease activity.

ANTIVIRAL RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Jackelyn Murray et al.

Summary: Research shows that probenecid effectively blocks SARS-CoV-2 replication in mammalian cells and a hamster model, with plasma concentrations up to 50 times higher than the IC90 value achievable for 24 hours following a single oral dose, indicating its potential clinical utility in controlling SARS-CoV-2 infection in humans.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis

Kirill Gorshkov et al.

ACS NANO (2020)

Add to Collection

Article Pharmacology & Pharmacy

Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model

Jianling Yang et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Article Chemistry, Medicinal

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

Wei Zhu et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Add to Collection

Article Chemistry, Medicinal

Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles

Catherine Z. Chen et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Add to Collection

Article Chemistry, Medicinal

Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay

Quinlin M. Hanson et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Add to Collection

Article Chemistry, Medicinal

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

Jonathan H. Shrimp et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Exploring different approaches to improve the success of drug discovery and development projects: a review

Geoffrey Kabue Kiriiri et al.

FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES (2020)

Add to Collection

Review Endocrinology & Metabolism

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Awadhesh Kumar Singh et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)

Add to Collection

Article Oncology

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients

Zong-Han Yao et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Article Virology

Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro

Patricia A. Jorquera et al.

JOURNAL OF VIROLOGY (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Host-directed therapies for bacterial and viral infections

Stefan H. E. Kaufmann et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond

Shuvam Chaudhuri et al.

ANTIVIRAL RESEARCH (2018)

Add to Collection

Article Pharmacology & Pharmacy

The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression

Tobias Schraeder et al.

ANTIVIRAL RESEARCH (2018)

Add to Collection

Article Virology

Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression

Yuan Zhou et al.

VIROLOGICA SINICA (2018)

Add to Collection

Review Microbiology

Approved Antiviral Drugs over the Past 50 Years

Erik De Clercq et al.

CLINICAL MICROBIOLOGY REVIEWS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults

Jonathan M. Zenilman et al.

ANTIVIRAL RESEARCH (2015)

Add to Collection

Review Biochemistry & Molecular Biology

Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens

Victoria A. Meliopoulos et al.

FASEB JOURNAL (2012)

Add to Collection

Article Gastroenterology & Hepatology

The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

Fernando E. Membreno et al.

CLINICS IN LIVER DISEASE (2011)

Add to Collection

Review Medicine, Research & Experimental

Genome-wide screening using RNA interference to study host factors in viral replication and pathogenesis

Laurent Houzet et al.

EXPERIMENTAL BIOLOGY AND MEDICINE (2011)

Add to Collection

Article Cell Biology

Probenecid, a gout remedy, inhibits pannexin 1 channels

William Silverman et al.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)

Add to Collection

Article Virology

Virus replication in engineered human cells that do not respond to interferons

DF Young et al.

JOURNAL OF VIROLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.